Press release content from Globe Newswire. The AP news staff was not involved in its creation.
AB Science announces that a new independent publication confirms that masitinib has anti-vital .
AB ScienceJanuary 25, 2021 GMT
NEW INDEPENDENT PUBLICATION CONFIRMS THAT MASITINIB HAS ANTI-VIRAL ACTIVITY AGAINST THE SARS-COV-2 VIRUS
IN VITRO AND IS A PROMISING CANDIDATE FOR TREATING COVID-19
Paris, 25 January 2021, 8.30am CET
AB Science SA (NYSE Euronext - FR0010557264 - AB) today announced the publication of preclinical study results with masitinib in COVID-19. Research led by scientists from the Institute of Human Virology (Guangzhou, China) has been published in the peer-reviewed journal
mBIO (a journal of the American Society for Microbiology). The article, entitled ‘Engineering a reliable and convenient SARS-CoV-2 replicon system for analysis of viral RNA synthesis and screening of antiviral inhibitors’,[1] is freely accessible online from the mBio journal site https://mb
Organicell Regenerative Medicine, Inc. (OTCBB: BPSR) (the “
Company”), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that it is now current in its SEC reporting requirements under the Securities Exchange Act of 1934, as amended (the “
Exchange Act”).
Upon filing is Quarterly Report on Form 10-Q for the Quarter ended July 31, 2020 on December 18, 2020, the Company became current in its SEC reporting requirements under the Exchange Act. The Company had not been current in such filings since the filing of its Quarterly Report on Form 10-Q for the Quarter ended July 31, 2017. The Company’s periodic filings with the SEC under the Exchange Act may be reviewed online at the SEC’s website, www.sec.gov.
Organicell Regenerative Medicine, Inc Becomes Current with SEC Reporting Requirements - Press Release digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.
Bruno Dubois
Bruno Dubois is currently Professor of Neurology at the Neurological Institute of the Salpétrière University Hospital at Paris, University Pierre et Marie Curie Paris VI. He is Director of the Behavioural Neurology Department and of the Dementia Research Center at the Hospital. He is also Director of the Research Unit Inserm U-610 of the ICM (Institut du Cerveau et de la Moelle Epinière) of the Hospital. He is coordinator of the National Reference Center on Rare Dementias and of the National Reference Center for young-onset Alzheimer patients. He is President of the Scientific Committee of France-Alzheimer and of IFRAD (International Fund Raising for Alzheimer s disease), consultant for the Human Frontier Program and Expert of the French Agency of Drugs. He is a member of the European Alzheimer Disease Consortium (EADC). He has published on anatomical and biochemical studies on the central cholinergic systems in rodents and humans; on cognitive neuropharmacology; an
AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer s disease Paris Stock Exchange:AB globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.